MARKET

REGN

REGN

Regeneron Pharmaceuticals
NASDAQ
736.08
-5.40
-0.73%
After Hours: 735.60 -0.48 -0.07% 16:06 11/29 EST
OPEN
739.90
PREV CLOSE
741.48
HIGH
740.00
LOW
727.00
VOLUME
515.10K
TURNOVER
0
52 WEEK HIGH
769.63
52 WEEK LOW
538.01
MARKET CAP
80.16B
P/E (TTM)
15.53
1D
5D
1M
3M
1Y
5Y
Insider Sell: Regeneron Pharmaceuticals
Insider Sell: Regeneron Pharmaceuticals
MT Newswires · 1d ago
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders sold US$7.0m worth of stock suggesting impending weakness.
In the last year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a substantial stake in the company...
Simply Wall St. · 3d ago
Regeneron (REGN) Outperforms YTD: What's in Store for 2023?
Regeneron (REGN) has had a good run in 2022 so far and the momentum should continue in 2023 as well.
Zacks · 4d ago
Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update
Updates from CTMX and APLS are the key highlights from the biotech sector during the past week.
Zacks · 6d ago
Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo® (cemiplimab) as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or af...
PR Newswire · 11/22 12:00
Regeneron Pharmaceuticals Obtains European Commission's Approval for Libtayo as Monotherapy in Cervical Cancer
Regeneron Pharmaceuticals Obtains European Commission's Approval for Libtayo as Monotherapy in Cervical Cancer
MT Newswires · 11/22 07:33
CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron
CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.
Zacks · 11/18 18:18
Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'
Benzinga · 11/18 13:36
More
About REGN
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.

Webull offers kinds of Regeneron Pharmaceuticals Inc stock information, including NASDAQ:REGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading REGN stock methods without spending real money on the virtual paper trading platform.